Rana Al-Hallaq
Director/Board Member at Blade Therapeutics, Inc.
Profile
Rana Al-Hallaq, PHD is Executive Director, WWBD and Partner at Pfizer Ventures.
Rana is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer.
She currently has responsibility for Pfizer’s investments in Arkuda Therapeutics, Autifony Therapeutics, Biograph55, Blade Therapeutics, Jnana Therapeutics, Magnolia NeuroSciences, Mitokinin, Montis BioSciences, ReCode Therapeutics, RefleXion Medical, Triplet Therapeutics, and Vivet Therapeutics.
Her prior investment responsibilities include Cortexyme and VectivBio.
She is also responsible for managing investments in the Dementia Discovery Fund and the Health Enterprise Partners Fund.
Prior to her current role, Rana was a Transactionalist in Worldwide Business Development at Pfizer where she was responsible for negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas.
Rana joined Pfizer in 2015 as an Early Candidate Clinical Lead where she advised early clinical programs in CNS to ensure alignment with business strategies.
Prior to joining Pfizer, she held roles at Allergan (formerly Actavis, formerly Forest Laboratories), first in Clinical Development Psychiatry as scientific and operational lead on Phase 2 and Phase 3 studies investigating novel treatments for Major Depressive Disorder and schizophrenia, and later in Business Development where she assessed and executed on a number of acquisitions and licenses across therapeutic areas.
She began her training as a research fellow at the National Institutes of Health.
Rana received her BA in Biology from Hamilton College and holds a PhD in Neuroscience from Georgetown University Medical Center.
Rana Al-Hallaq active positions
| Companies | Position | Start |
|---|---|---|
Blade Therapeutics, Inc.
 Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Director/Board Member | - |
Montis Biosciences BV
 Montis Biosciences BV BiotechnologyHealth Technology Montis Biosciences BV engages in the development of immune-oncology therapeutics targetting the intersection between vascular dysfunction and immune suppression to treat solid tumors. It offers target screening and assay platform to discover novel targets modulating interactions between tumor endothelial cells and perivascular macrophages. The company was founded by Peter Carmeliet and Massimiliano Mazzone and is headquartered in Meise, Belgium. | Director/Board Member | - |
Pfizer Venture Investments LLC
 Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | Private Equity Investor | 2018-07-31 |
Reflexion Medical, Inc.
 Reflexion Medical, Inc. Medical SpecialtiesHealth Technology Reflexion Medical, Inc. develops medical devices. Its products include marketwired resonate and influencers, news distribution, IR and PR hosted newsroom and media database. The company was founded by Akshay Nanduri and Samuel Mazin in 2009 and is headquartered in Hayward, CA. | Director/Board Member | 2021-05-26 |
Vivet Therapeutics SAS
 Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Director/Board Member | - |
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Director/Board Member | - |
Mitokinin, Inc.
 Mitokinin, Inc. BiotechnologyHealth Technology Mitokinin, Inc. develops kinase neo-substrates for the treatment of neurodegenerative and mitochondrial diseases. The company was founded by Kevan Shokat, Nicholas Hertz, and Daniel de Roulet Jr. and is headquartered in New York, NY. | Director/Board Member | - |
Former positions of Rana Al-Hallaq
| Companies | Position | End |
|---|---|---|
| FOREST LABORATORIES, INC. | Private Equity Investor | 2015-06-30 |
Training of Rana Al-Hallaq
| Hamilton College (New York) | Undergraduate Degree |
| Georgetown University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | Finance |
Reflexion Medical, Inc.
Reflexion Medical, Inc. Medical SpecialtiesHealth Technology Reflexion Medical, Inc. develops medical devices. Its products include marketwired resonate and influencers, news distribution, IR and PR hosted newsroom and media database. The company was founded by Akshay Nanduri and Samuel Mazin in 2009 and is headquartered in Hayward, CA. | Health Technology |
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Commercial Services |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Health Technology |
Vivet Therapeutics SAS
Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Health Technology |
Mitokinin, Inc.
Mitokinin, Inc. BiotechnologyHealth Technology Mitokinin, Inc. develops kinase neo-substrates for the treatment of neurodegenerative and mitochondrial diseases. The company was founded by Kevan Shokat, Nicholas Hertz, and Daniel de Roulet Jr. and is headquartered in New York, NY. | Health Technology |
Montis Biosciences BV
Montis Biosciences BV BiotechnologyHealth Technology Montis Biosciences BV engages in the development of immune-oncology therapeutics targetting the intersection between vascular dysfunction and immune suppression to treat solid tumors. It offers target screening and assay platform to discover novel targets modulating interactions between tumor endothelial cells and perivascular macrophages. The company was founded by Peter Carmeliet and Massimiliano Mazzone and is headquartered in Meise, Belgium. | Health Technology |
- Stock Market
- Insiders
- Rana Al-Hallaq